Talha Badar, Hematology/Oncology Specialist at Mayo Clinic shared a post on X:
“83F with chronic-phase CML on imatinib × 6 years BCR::ABL1 p210 at MR4 – excellent response. But new Ph-related cytogenetic abnormalities prompted deeper investigation.
Qualitative assay revealed the rare e19a2 transcript -> p230 fusion which is invisible to standard p210 PCR.
Pearls:
- Rare BCR::ABL1 transcripts (p230) evade routine monitoring.
- Cytogenetic-molecular discordance = investigate atypical transcripts.
- Morphology + cytogenetics + molecular are complementary – never rely on one alone.
When the biology doesn’t fit the PCR, trust the discrepancy.
Have you encountered p230 or another atypical BCR::ABL1 transcript that changed management?”
Other articles featuring Talha Badar on OncoDaily.